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OBJECTIVES We sought to determine the relationship between osteoprotegerin (OPG) and clinical
outcomes in patients with heart failure (HF) after acute myocardial infarction (AMI).
BACKGROUND Arterial calcification is a prominent feature of arterial atherosclerosis and is associated with
the occurrence of AMI. Osteoprotegerin is a recently discovered member of the tumor
necrosis superfamily that may link the skeletal with the vascular system.
METHODS We assayed plasma OPG levels in 234 patients with AMI complicated with HF and their
relation to adverse outcomes during follow-up in patients randomly assigned to angiotensin-
converting enzyme inhibition or angiotensin II antagonism. Blood was sampled at baseline
(median three days after AMI), one month, and at one and two years.
RESULTS Elevated plasma levels of OPG at baseline were associated with adverse outcomes during a
median of 27 months follow-up; OPG remained an independent prognostic indicator also
after adjustment for other known predictors of mortality and cardiovascular events after AMI
(e.g., creatinine clearance, N-terminal B-type natriuretic peptide, high-sensitivity C-reactive
protein). In non-survivors, plasma OPG levels were persistently elevated during longitudinal
testing, suggesting that OPG may be of value for monitoring patients at risk.
CONCLUSIONS Osteoprotegerin is a novel marker for cardiovascular mortality and clinical events in patients
with AMI complicated with HF. These findings are compatible with the hypothesis
suggesting a possible association between mediators of bone homeostasis and cardiovascular
disease. (J Am Coll Cardiol 2004;44:1970–6) © 2004 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.06.076Cardiology Foundation
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orterial calcification and mineral deposition are prominent
eatures of atherosclerosis, and relationships between the
xtent of coronary artery calcification and the occurrence of
cute myocardial infarction (AMI) (1) and death have been
emonstrated (2). Furthermore, noncollagenous, bone
See page 1977
atrix-associated proteins such as osteocalcin, osteopontin,
nd osteonectin have been identified at sites of calcification
3–5), and endochondral bone formation in the coronary
asculature has been suggested as a possible mechanism of
oronary calcification (6). Thus, there seem to be similarities
etween vascular and skeletal calcification suggesting a
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Manuscript received March 1, 2004; revised manuscript received June 1, 2004,
ccepted June 9, 2004.egulatory role for osteogenic and calcitropic factors in the
evelopment of cardiovascular disease.
Osteoprotegerin (OPG) is a member of the tumor
ecrosis factor (TNF) receptor superfamily that can func-
ion as a soluble decoy receptor by binding receptor activator
f nuclear factor-B ligand (RANKL), thus competitively
nhibiting interaction between RANKL and its receptor.
hese mediators have been identified as candidate factors
or paracrine signaling in bone metabolism, but are also
nvolved in immune responses by modulating T-cell func-
ion and antibody response (7). Furthermore, messenger
ibonucleic acid and protein expression of OPG and
ANKL have been detected in myocardial tissue and
therosclerotic plaques (3,5). Moreover, elevated OPG lev-
ls have been associated with the progression of vascular
alcification in patients receiving long-term hemodialysis
8,9), with the presence and severity of coronary artery
isease (10,11), with cardiovascular mortality in elderly
omen (12), and recently also as a risk factor of cardiovas-
ular disease in the general population (13).
Patients with AMI frequently show evidence of heart
ailure (HF) with a high risk of morbidity and mortality. To
urther elucidate the potential role of OPG in cardiac
isease, we prospectively investigated the prognostic value
f circulating OPG levels in patients with AMI complicated
ith HF.
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tudy population. The design and main results of the
ptimal Trial in Myocardial Infarction with Angiotensin II
ntagonist Losartan (OPTIMAAL) have previously been
eported in detail (14). Briefly, 5,477 patients with AMI
omplicated with HF during the acute phase were randomly
ssigned and titrated to a target dose of losartan (50 mg
very day) or captopril (50 mg three times a day) as
olerated. Median randomization time was three days, and
atients were followed for a median 2.7 years for mortality
nd morbidity end points. Inclusion criteria confirmed AMI
nd left ventricular dysfunction (i.e., left ventricular ejection
raction [LVEF] 35% or a left ventricular end-diastolic
imension 65 mm) and/or HF during the acute phase as
uggested by one or more of the following: treatment with
iuretic or intravenous vasodilator therapy for HF, pulmo-
ary rales, third heart sound, persistent sinus tachycardia
100 beats/min), or radiographic evidence of pulmonary
ongestion (14). The present study was a prospectively
esigned substudy of the main OPTIMAAL trial compris-
ng 234 consecutively included patients performed at six
enters designed to analyze plasma/serum levels of cytokines
nd other inflammatory mediators. There were no signifi-
ant differences in baseline characteristics between the
reatment groups. Except for a higher proportion of statin
sers and a lower incidence of re-infarctions, there were no
ifferences in baseline characteristics between this substudy
nd the OPTIMAAL main trial. No hemodialysis patients
ere included in this study. For comparison, plasma OPG
evels were also measured in 15 age- and gender-matched
ealthy controls.
lood sampling. Blood samples were obtained at baseline
nd after one month, one year, and two years. Samples were
rawn after an overnight fast into pyrogen-free vacuum
lood collection tubes with EDTA (OPG and high-
ensitivity C-reactive protein [hsCRP]) or EDTA and apro-
inin (N-terminal B-type natriuretic peptide [N-BNP]).
ubes were immediately immersed in melting ice, centri-
uged (1,000 g and 4°C for 15 min) within 15 min, and
lasma was stored at 80°C in multiple aliquots until
Abbreviations and Acronyms
AMI  acute myocardial infarction
HF  heart failure
hsCRP  high-sensitivity C-reactive protein
LVEF  left ventricular ejection fraction
N-BNP  N-terminal B-type natriuretic peptide
OPG  osteoprotegerin
OPTIMAAL  Optimal Trial in Myocardial Infarction
with Angiotensin II Antagonist
Losartan
RANKL  receptor activator of nuclear factor-B
ligand
TNF  tumor necrosis factornalyzed. Samples were thawed 3 times. aiochemical analysis. Plasma OPG was quantified by an
nzyme immunoassay using commercially available matched
ntibodies (R&D Systems, Minneapolis, Minnesota). The
ntra- and interassay coeffcients of variation were 3.6% and
0.6%, respectively (15). The sensitivity, defined as the
ean  3 SD of the zero standard, was calculated to be 15
g/ml; N-BNP was analyzed as previously described (16).
lasma levels of hsCRP were measured by an immuno-
ephelometric assay performed on the Behring nephelom-
ter (BN II, Dade Behring, Liederbach, Germany).
tatistical methods. Kaplan-Meier survival curves were
enerated, and the log-rank test was used to compare
urvival rates in patients with high and low OPG levels.
ifferences in continuous variables were compared using
ann-Whitney U while the chi-square test was used for
roportions. Associations between baseline risk factors,
PG concentrations (quartiles), and cardiovascular events
ere analyzed by univariate analysis a priori, and if p  0.2,
ere subsequently included in a forced or forward condi-
ional multivariate Cox regression. Cardiovascular events
end points) were: nonfatal myocardial infarction (n  40),
ardiovascular death (n  26), total mortality death (n 
2), composite end point (all of the former plus stroke, n 
0) (n  65). For investigating treatment effects, repeated-
easures analysis of variance was performed a priori with
ime and treatment as fixed factors and subject as random;
PG was not normally distributed at baseline as evaluated
y the Kolmogorov-Smirnov test, and, therefore, trans-
ormed before inclusion in the general linear model. Prob-
bility values are two-sided with p  0.05 being considered
tatistically significant.
ESULTS
t baseline the study population had significantly raised
lasma OPG levels compared with age- and gender-
atched (not risk-factor-matched) healthy controls (Fig. 1),
ith a median of 3.0 ng/ml (interquartile range 2.1 to
.1 ng/ml).
lasma OPG during follow-up. During follow-up,
lasma OPG levels decreased markedly after one month,
igure 1. Plasma osteoprotegerin (OPG) levels during two years’
ollow-up in relation to randomization status. Shaded area represents 95%
onfidence interval for healthy age- and gender-matched controls. BL 
aseline.nd remained at this level during the rest of the sampling
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OPG in Acute Myocardial Infarction November 16, 2004:1970–6eriod (i.e., 24 months), with no differences between
ngiotensin-converting enzyme inhibition and selective an-
iotensin II antagonism (Fig. 1). Moreover, although there
as a decline in OPG, plasma levels were markedly in-
reased compared with controls throughout the study
eriod.
ssociation between OPG levels and baseline clinical
nd biochemical variables. When baseline OPG levels in
he study population were divided into quartiles, we found
hat patients with high OPG levels were significantly older,
ad higher N-BNP and hsCRP levels, and a higher rate of
iuretic and beta-blocker use at discharge (Table 1). Al-
hough patients with high OPG levels had a lower creati-
ine clearance, those patients with normal creatinine clear-
nce had significantly increased OPG compared with
ontrols. There were no significant differences in other
aseline variables between the quartiles (Table 1). All the
omen in this study were post-menopausal, and 11 (16%)
eceived hormone replacement therapy, with no differences
n OPG levels between those receiving and not receiving
ormone replacement therapy.
PG levels at baseline and cardiovascular events. Dur-
ng follow-up 32 patients (14%) died. Kaplan-Meier sur-
ival curves according to OPG quartiles at baseline are
resented in Figure 2 and show a higher mortality rate in
hose with high OPG levels (i.e., 4.1 ng/ml). Moreover,
PG levels were significantly lower in long-term survivors
han in patients dying from all-cause mortality (2.8 vs.
.2 ng/ml, p  0.001) or cause-specific cardiovascular
vents (2.8 vs. 4.2 ng/ml, p 0.001); OPG levels at baseline
able 1. Baseline Characteristics According to OPG Levels
OPG <2.1 O
emographics
n 56
Age (yrs) 63  8
Male (%) 70
BMI (kg/m2) 27  3
Smoking (%) 41
istory
Hypertension (%) 35
Previous myocardial infarction (%) 10
Diabetes (%) 4
edication
Diuretics (%) 63
Beta-blocker (%) 89
Statins (%) 71
ASA (%) 96
Warfarin (%) 20
nterior, lateral infarct location (%) 66
illip class (II–IV) (%) 71
reatinine clearance 85 ml/min (%) 11
sCRP (mg/l) 44  45
-BNP (pmol/l) 873  570 1
ata are mean  SD.
ASA  acetylsalicylic acid; BMI  body mass index; hsCRP  high-sensit
steoprotegerin; Statins  hydroxymethylglutaryl coenzyme A reductase inhibitors.n patients experiencing recurrent, nonfatal AMI during
d
qollow-up were not statistically different from those spared
his end point (3.6 vs. 3.2 ng/ml, p  0.128). Finally, we
onstructed a composite end point consisting of all-cause
ortality, stroke, and nonfatal myocardial infarction and
ound that these patients also had significantly higher OPG
evels than the rest of the study group (3.7 vs. 3.1 ng/ml, p
0.003). The association between OPG levels at baseline
nd clinical events during follow-up is illustrated in Figure
, showing the unadjusted risk estimates based on baseline
PG quartiles.
Quartiles
p Value<3.0 OPG <4.1 OPG >4.1
6 57 56
 10 69  10 72  11 0.001
1 74 66 0.841
 4 25  3 26  3 0.119
2 33 32 0.040
0 26 43 0.235
3 11 15 0.869
6 9 18 0.065
3 83 80 0.037
0 70 61 0.003
6 72 48 0.028
8 98 93 0.369
8 12 21 0.610
0 53 52 0.117
2 86 84 0.205
6 36 52 0.001
 39 81  77 98  77 0.001
 654 1,406  584 1,801  749 0.001
-reactive protein; N-BNP  N-terminal probrain natriuretic peptide; OPG 
igure 2. Kaplan-Meier curves showing the cumulative incidence of deathPG
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,309uring the entire study (median follow-up 27 months), according to the
uartiles (Q) of plasma osteoprotegerin at enrollment.
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November 16, 2004:1970–6 OPG in Acute Myocardial Infarctionther baseline predictors of cardiovascular events. The
ssociations between potential confounder variables and
ll-cause mortality and cardiovascular events are summa-
ized in Table 2. Several variables were univariate predictors
f all-cause mortality and cardiovascular death, including
ge, diabetes, previous myocardial infarction, hypercholes-
erolemia, creatinine clearance, and N-BNP. In general,
hese variables were significant predictors of the composite
nd point as well. Still, for all these end points we included
ariables with associations p 0.2 in a multivariate analysis.
ultivariate analysis. In a multivariate model, adjusting
or potential confounders (see the preceding text), plasma
PG levels were still associated with long-term, all-cause
ortality, cardiovascular death, and the composite end
oint (Table 3). Similar results were obtained with both
tepwise (Table 3) and forced addition of independent
redictors as well as by entering all potential confounders,
egardless of association with adverse events (all variables in
able 2). Thus, high plasma OPG levels measured during
he acute phase after AMI remain an independent and
trong determinant of all-cause mortality and cardiovascular
eath in this study population.
igure 3. Unadjusted risk ratios for quartiles (Q) of osteoprotegerin at
aseline in relation to incidence of angina, nonfatal myocardial infarction
MI), cardiac death, total mortality, or the composite end point (all-cause
ortality, stroke, and nonfatal MI). *p 0.05; †p 0.01; ††p 0.001 vs.
1.
able 2. Univariate Associations Between Baseline Variables and
oint (All-Cause Mortality, Stroke, or Nonfatal MI)
All-Cause Mortality
RR (95% CI) p Value
ge 67 yrs* 11.4 (3.3–33.5) 0.001
ale gender 0.9 (0.4–2.1) 0.837
ypertension 2.0 (0.9–4.3) 0.074
revious myocardial infarction 3.7 (1.5–9.3) 0.007
moke 0.5 (0.2–1.1) 0.095
iabetes mellitus 2.6 (1.0–6.7) 0.069
nterior, lateral infarct location 0.7 (0.3–1.5) 0.438
illip class (II–IV), % 1.3 (0.5–3.7) 0.808
reatment (losartan or captopril) 1.1 (0.5–2.4) 0.849
reatinine clearance 85 ml/min* 7.1 (3.0–17.0) 0.001
-BNP 1,246 pM* 2.1 (1.0–4.4) 0.060
sCRP 50 mg/l* 0.7 (0.3–1.6) 0.432Dichotomized at median.
CI  confidence interval; hsCRP  high-sensitivity C-reactive protein; MI  myocardlasma OPG and other parameters of HF. Because this
s an HF population, we also compared the prognostic value
f OPG with other prognostic markers in this patient
opulation; LVEF was not routinely recorded in this
ubstudy, but LVEF data (baseline) were available from 69
atients showing no relationships with cardiovascular or
omposite end points (data not shown) or plasma OPG (r
0.169, p  0.168). Although these findings suggest that
PG remains a significant predictor even if LVEF has been
orrected for, caution is needed when interpreting these data
ecause of a low number of LVEF observations. As for
-BNP, an important prognostic marker in HF patients,
e found a significant correlation with OPG levels both at
aseline (r  0.51, p  0.001) and at all time points during
he study. However, OPG remained a significant predictor
f death also when correcting for N-BNP (Table 3). Thus,
t seems that plasma OPG may not only reflect the degree
f HF, but may independently predict mortality in these
ubjects. Moreover, we found only a weak correlation
etween OPG levels and the degree of myocardial damage
uring AMI as assessed by creatinine kinase-MB (CK-MB)
n  159, r  0.141, p  0.042), but not troponin T (n 
26, r  0.044). Thus, although these markers of myocar-
ial damage were not available in all patients; our data
uggest that increased CK-MB/troponin T after AMI is not
major confounder in the present study.
PG during longitudinal follow-up in relation to car-
iovascular events. As described previously, plasma OPG
evels decreased early (i.e., after one month) and remained at
his level during the rest of the study period (Fig. 1). In fact,
he intraindividual variation from one month to two years
as 11  8% (mean  SD). When comparing OPG levels
n survivors and non-survivors (all-cause mortality), we
ound that the latter group had persistently higher OPG
evels at all time points during follow-up (Fig. 4). Further-
ore, the prognostic value of plasma OPG measurements in
elation to all-cause mortality and cardiovascular events
ause Mortality, Cardiovascular Death, or the Composite End
Cardiovascular Death Composite End Point
RR (95% CI) p Value RR (95% CI) p Value
8.2 (2.4–27.9) 0.001 3.1 (1.7–5.8) 0.001
1.1 (0.4–2.6) 1.000 1.1 (0.6–2.2) 0.405
2.8 (1.2–6.3) 0.018 1.1 (0.6–2.0) 0.744
3.6 (1.4–9.5) 0.011 3.3 (1.5–7.4) 0.003
0.4 (0.2–1.0) 0.054 0.7 (0.4–1.3) 0.281
3.1 (1.2–8.3) 0.027 2.0 (0.9–4.5) 0.103
0.7 (0.3–1.6) 0.537 1.0 (0.5–1.7) 0.869
1.1 (0.4–3.1) 1.000 1.2 (0.6–2.6) 0.605
1.0 (0.4–2.1) 1.000 0.8 (0.5–1.5) 0.498
6.7 (2.7–16.8) 0.001 3.4 (1.9–6.2) 0.001
2.2 (1.0–5.0) 0.048 1.4 (0.8–2.6) 0.226
0.7 (0.3–1.5) 0.305 1.3 (0.7–2.3) 0.450All-Cial infarction; N-BNP  N-terminal probrain natriuretic peptide; RR  risk ratio.
d
i
D
T
o
a
p
a
n
t
i
d
i
n
t
g
p
f
d
r
v
m
a
c
p
r
d
h
f
c
s
o
c
h
m
p
O
a
c
r
a
(
a
l
a
s
O
a
a
f
b
c
c
s
i
c
F
i
s
S
g
T
N
A
C
C
p
1974 Ueland et al. JACC Vol. 44, No. 10, 2004
OPG in Acute Myocardial Infarction November 16, 2004:1970–6uring follow-up increased at one month and one year after
nclusion compared with baseline (Table 4).
ISCUSSION
he present study demonstrates that elevated plasma levels
f the soluble decoy receptor OPG are associated with
dverse prognosis in patients who develop HF in the acute
hase after AMI. Furthermore, the predictive value of OPG
t baseline provided risk prediction independent of creati-
ine clearance, N-BNP, hsCRP, and other known predic-
ors of mortality and cardiovascular events after AMI. Of
mportance, OPG remained a significant predictor of car-
iovascular death also when correcting for N-BNP, an
mportant prognostic marker in HF patients. Finally, in
on-survivors plasma OPG levels were not only increased in
he acute phase of AMI, but also during follow-up, sug-
esting that OPG may be valuable for monitoring HF
atients both immediately after AMI as well as during
ollow-up.
An increasing number of osteogenic factors have been
etected in atherosclerotic plaques and received attention in
elation to vascular biology (3–5). The OPG/receptor acti-
ator of NF-kappaB system plays an important role in bone
igure 4. Plasma osteoprotegerin (OPG) levels during two-year follow-up
n survivors and non-survivors. *p 0.01; **p 0.001 non-survivors versus
urvivors. Four non-survivors died after the last sampling (two year).
able 3. Multivariate Models for All-Cause Mortality, Cardiac D
onfatal MI) During Follow-Up (Average 27 Months)
Hazard R
End Point Q1: OPG <2.1 Q2: OPG <
ll-cause mortality
Crude 1 1.4 (0.3–6.4
Age-adjusted 1 0.9 (0.2–4.3
Multivariate 1 2.9 (0.3–24.
ardiac death
Crude 1 1.0 (0.2–5.2
Age-adjusted 1 0.7 (0.1–3.6
Multivariate 1 2.1 (0.2–20.
omposite end point
Crude 1 1.1 (0.4–2.5
Age-adjusted 1 0.9 (0.4–2.2
Multivariate 1 1.1 (0.5–2.8
value, test of trend.
CI  confidence interval; MI  myocardial infarction; OPG  osteoprotegerin.c
haded area represents 95% confidence interval for healthy age- and
ender-matched controls. BL  baseline.etabolism, and, in the present study, we report a strong
ssociation between high plasma levels of OPG and in-
reased mortality and occurrence of cardiovascular events in
atients who develop HF after AMI, further supporting a
ole for mediators in bone metabolism in cardiovascular
isease. These findings support a recent study showing that
igh-serum OPG was found to be an independent risk
actor of progressive atherosclerosis and incident cardiovas-
ular disease in the general community (13). We found
ignificant associations between baseline levels of OPG and
ther risk factors for cardiovascular events such as age,
reatinine clearance, and circulating levels of N-BNP and
sCRP. However, when adjusting for these variables in a
ultivariate analysis, OPG levels remained a significant
redictor of fatal and nonfatal cardiovascular events. In fact,
PG at admission appeared to be a stronger predictor of
dverse events than N-BNP and hsCRP, two markers of
ardiovascular events that have received much attention
ecently (16).
Cross-sectional associations between circulating OPG
nd mortality have recently been shown in other populations
12,17). A major finding in the present study was that, in
ddition to being an excellent risk marker at baseline, OPG
evels were persistently high in non-survivors. In fact, the
ssociation with subsequent cardiovascular events was even
tronger during follow-up than at baseline, suggesting that
PG measurements may be used to monitor patients at risk
nd help identifying subgroups that may benefit from
ggressive intervention.
We can only speculate as to the source and mechanism
or the enhanced systemic OPG levels found in this study
ecause OPG is produced in many tissues including the
ardiovascular system, lung, kidney, intestine, bone, and
irculating immune cells (7,18). Moreover, the present
tudy was not designed to compare OPG levels after AMI
n those with and without post-infarction HF, and we
annot make any firm conclusion concerning the relative
, and Composite End Point (All-Cause Mortality, Stroke, or
95% CI) for Quartiles
Q3: OPG <4.1 Q4: OPG >4.1 p Value
2.1 (0.5–8.7) 9.1 (2.5–32.8) 0.001
1.3 (0.3–5.2) 4.3 (1.2–14.7) 0.003
3.9 (0.5–32.5) 12.5 (1.7–94.6) 0.001
1.7 (0.4–7.5) 7.7 (2.1–28.1) 0.001
1.1 (0.3–4.6) 3.8 (1.1–13.4) 0.005
3.3 (0.4–28.3) 11.2 (1.5–85.4) 0.002
1.1 (0.4–2.7) 3.5 (1.5–8.2) 0.002
1.0 (0.4–2.2) 2.3 (1.1–4.8) 0.011
1.2 (0.5–3.0) 2.9 (1.3–6.2) 0.007eath
atio (
3.0
)
)
9)
)
)
4)
)
)
)ontribution of ischemia and HF in itself to the raised OPG
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November 16, 2004:1970–6 OPG in Acute Myocardial Infarctionevels in the present study population. However, although
revious studies have reported high levels of OPG in
atients with angina (10,11), we have recently found raised
PG levels in chronic HF with no differences between
schemic and idiopathic cardiomyopathy (T. Ueland,
. Aukrust, submitted for publication, 2004), suggesting
hat HF in itself is a potent stimuli for OPG release.
mportantly, OPG expression has been demonstrated in
ifferent vascular cell types, and both coronary smooth
uscle cells and endothelial cells have been implicated as
ellular sources and targets of vascular OPG production
19,20).
Thus, the contribution by many recognized risk factors
e.g., diabetes) for mortality after uncomplicated AMI may
e cushioned in the present study by the impact of HF on
PG; OPG has been shown to play a role in the regulation
f the immune response and is regulated by the ligation of
everal cytokines involved in the inflammatory response
fter AMI. Thus, both CD40L, TNF-alpha, and
nterleukin-1-beta have been shown to enhance OPG ex-
ression in various cells (21,22), and these cytokines are
ersistently activated in the chronic phase during infarction
ealing (23–26). Moreover, in post-menopausal osteoporo-
is, human immunodeficiency virus infection, and Cushing’s
yndrome, high-serum OPG is suggested to reflect en-
anced RANKL activity (15,27). Thus, although OPG may
rotect against harmful effects of RANKL and TRAIL,
nother ligand for OPG (28), the strong association be-
ween high OPG and cardiovascular mortality could indi-
ate that plasma OPG level is a parameter of the overall
ctivity in the OPG/RANK system as well as a stable
arker of inflammation.
In the present study we found a rapid decline (i.e., within
ne month) in OPG levels, and the reason for this is at
resent unclear. However, several non-mutually exclusive
echanisms may exist. First, as mentioned above, OPG is a
otentially stable and reliable marker of inflammation, and
he early decrease in OPG may reflect attenuated inflam-
ation during the one month after AMI. Second, we have
ecently detected high OPG expression in myocardial tissue
rom both human and experimental HF (see the preceding
ext), and, although we found only a weak correlation
etween OPG levels and the degree of myocardial damage
uring AMI, we cannot exclude that the high OPG levels at
able 4. Unadjusted Risk Ratios for All-Cause Mortality and Ca
4.1 ng/ml [4th Quartile]) and Low (4.1 ng/ml [Quartiles 1 t
One Month
RR (95% CI) p Value
ngina 2.5 (0.6–10.9) 0.207
onfatal MI 17.9 (3.4–93.0) 0.001
ardiac death 22.4 (4.8–103.5) 0.001 1
eath 22.4 (4.8–103.5) 0.001
omposite 11.8 (2.3–60.5) 0.001
I  confidence interval; MI  myocardial infarction; RR  risk ratio.aseline, at least partly, reflect release from damaged myo-ardial tissue secondary to AMI. Finally, although the
resent study was not placebo controlled, we cannot rule out
he effects of angiotensin II blockade on regulating serum
PG because angiotensin II has been shown to upregulate
PG expression in vascular smooth muscle cells (29).
In summary, plasma OPG levels provide impressive
ndependent prognostic information in patients who de-
elop HF after AMI, both in the acute phase as well as
uring follow-up, representing a noninvasive tool for mon-
toring morbidity of mortality in these patients. Future
tudies must determine if these results apply solely to
ost-infarction HF or if OPG can provide prognostic
nformation for a wider group of AMI patients. Nonethe-
ess, the identification of OPG as a novel cardiovascular risk
arker suggests an association between mediators of bone
omeostasis and cardiovascular disease and supports a link
etween bone and vascular calcification.
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